The MarketWatch News Department was not involved in the creation of this content. MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
Repatha was first approved in 2015 and has since been used by more than 8 million patients globally. 5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...
Andy Coravos says offloading tedious tasks to AI has freed her to focus more on the things she loves, like singing and playing guitar. Andy Coravos has a new home helper—named Claude. She assigns her ...
MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have expanded public reimbursement of Repatha ® (evolocumab injection) for eligible ...
Christos Soteriou was 29 when he needed a quadruple bypass surgery. Four arteries in his heart had become so clogged with plaque that blood could no longer flow through them. Subscribe to read this ...
NEW ORLEANS — Patients with diabetes who have not been diagnosed with atherosclerotic cardiovascular disease would benefit by taking the PCSK9 inhibitor evolocumab to lower their LDL cholesterol to ...
NEW ORLEANS—Adding the PCSK9 inhibitor evolocumab (Repatha; Amgen) to statin therapy significantly cuts the risk of major cardiovascular events when compared with statins alone in high-risk patients ...
EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results